[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Therapy Market Research Reports & Industry Analysis

Defined as treatment of disabilities/illnesses (physical and mental), therapy represents an essential branch of medicine. This term is widely used by psychologists to describe the session between them and patients. Depending on an illness, different therapies types are applied. Therapies may be aimed at the prevention of the disease occurrence, stopping its further progress or preventing an outbreak. They may be also used to improve a patient’s comfort.

Therapies are classified on the basis of energy (e.g. phototherapy and thermotherapy), human interaction (for instance, psychotherapy and psychotherapy) and matter (e.g. gene therapy and biotherapy), etc.

The Catalogue is an unprecedented source of research reports analyzing the therapy market in detail. The reports uncover the market sizing and segmentation, its present standing and future prospects. The research studies investigate the competitive environment and contain majors’ profiles. Market igniters and limiters are scrutinized, and trends and future opportunities are unveiled in the reports.

Publications found: 1,145
Sort by:

China Pollution Treatment Medical Materials Mfg. Industry Profile - CIC2665

US$ 580.00

... on distribution of and difference in performance in regions of Mainland China in terms of the pollution treatment medical materials mfg. industry; To figure out the hot ... for pollution treatment medical materials mfg. industry, find out the potential provinces and cities suitable for investment as well as the ...

June 2013 24 pages

Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023

US$ 2,635.00

... Drugs and related technologies to transform the market Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging Deep ... there, helping you stay ahead. Eight ways Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 helps you In particular ...

June 2013 149 pages

Global Gene Therapy Market Analysis

US$ 1,200.00

... to boost the growth. According to RNCOS’ new research report, “Global Gene Therapy Market Analysis”, major focus has been made on the ongoing ... therapy include cardiac conditions, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. ...

May 2013 110 pages

Para IV Plus Database

US$ 8,000.00

... undisclosed settlement dates, based on available facts. In other words, Para IV Plus is not merely a database but is a tool with in-depth insights for every ... gives list of potential API buyers To a pharma company desirous of banking on the Para IV litigations, this tool will help them strategize their entry ...

April 2013

Japan Pharma Database

US$ 15,000.00

Pricing: Japan Database: $15,000/- subscription p/a Formulating a competitive landscape of various therapeutic classes in Japan is challenging viz a viz the US and EU markets ... reliable Source in public domain 5. Large contribution of ‘Japan Only’ products - difficult to make competitive landscapes for overseas ...

April 2013

ENDOCYTE - Small and Powerful Targeted Therapy!

US$ 140.00

Endocyte’s (ECYT) SMDC technology platform and drug pipeline caught investor’s ... our initiation report released on 19th April, 2013 on ECYT titled “Small and Powerful Targeted Therapy!

April 2013 11 pages

Global Irritable Bowel Syndrome (IBS) Market: Trends & Opportunities (2012-2017)

US$ 700.00

... titled ‘Global Irritable Bowel Syndrome Market: Trends and Opportunities (2012-17)’ provides an in depth analysis of IBS market on a global level. The report presents the global market sizing of IBS and ... Sucampo Executive Summary Irritable Bowel Syndrome or IBS is a gastrointestinal disorder in which the colon muscle contracts more readily. The high prevalence of this syndrome could be estimated ...

March 2013 50 pages

Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunomodulators, Immunosuppressant, Copaxone, Avonex, Gilenya, Tysabri, Betaseron, Tecfidera, Rebif, Ampyra, Aubagio, Extavia, Plegridy, Alemtuzumab, Glatopa, Siponimod, Ocrelizumab, Laquinimod, Zinbryta), By Mode of Administration (Oral, Injectable, Intravenous) And Segment Forecasts To 2024

US$ 5,950.00

... one of the highest impact rendering drivers of the multiple sclerosis therapeutics market. Many organizations over the globe are actively involved in ... high prescription rates & price North America dominated the overall multiple sclerosis therapeutics market with revenue estimates at over 13.0 billion in 2015. ...

March 2013 86 pages

UAE IVF Treatment Market Analysis

US$ 600.00

... be prevented. “UAE IVF Treatment Market Analysis” research report gives detailed information on following aspects related to booming IVF treatment market in UAE: Current Market Scenario IVF Treatment Market Potential Treatment cycle & Birth Rate Fertility Treatment Loan ...

March 2013 68 pages

HIV - KOL Insight and Consensus Outlook Modules

US$ 7,495.00

... FirstWord research is provided in two comprehensive modules: The KOL Insight: HIV module provides a complete review underpinned by exclusive in-depth interviews with ... Protease inhibitors CCR5 inhibitor Expert Opinion for Real World Insights The data and analysis in the report is enriched through the ...

February 2013 183 pages

Therapeutic Class Report Overview - Future Of GPR Agonist

US$ 1,000.00

... GLP-1 secretion in glucose depended manner is the key trait of this class. Through this, GPR agonist controls hyperglycemia without hypoglycemia, and ...

February 2013 20 pages

Therapeutic Class Report Overview - Hemophilia

US$ 2,000.00

Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors – Factor VIII (FVIII) and Factor IX (proteins in blood that control bleeding). Plasma-derived FVIII and FIX proteins were used ...

February 2013 47 pages

Cellular Therapy and Cord Blood 2013 Market Report

US$ 2,119.00

... is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences. In this ... . Select Biosciences has also provided a detailed quantitative analysis of the cord blood field as it is rapidly evolving. Our coverage provides hard numbers ...

January 2013 172 pages

Epigenetic Therapies and Technologies: World Market Prospects 2013-2023

US$ 2,400.00

... Our work explains, exploring many issues. What affects the application of epigenetics? Our report discusses issues and events affecting that science, ... and commercial possibilities. Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you To sum up, our investigation ...

January 2013 195 pages

Competitor Analysis: Enzyme Replacement Therapies

US$ 403.00

... Intelligence Report Enzyme Replacement & Enhancement Therapies (ERT) as of January 2013 provides a competitor analysis in the development pipeline of novel enzyme replacement therapies and of enzyme enhancement therapies to treat human genetic diseases/lysosomal storage diseases and exocrine pancreatic ...

January 2013 74 pages

U.S. Market for Fetal and Neonatal Monitoring Devices - (Part of Segment Series)

US$ 2,995.00

... Drivers & Limiters Mergers & Acquisitions Customer Feedback and Market Monitoring SubSegments Included: Fetal and neonatal monitoring Invasive and Non-Invasive ... and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The ...

November 2012 65 pages

Top 100 Dental Practices (Denmark)

US$ 1,250.00

This report is an in-depth financial evaluation of the Denmark Dental Practices. Using the unique Plimsoll method of analysis, each of the largest 100 companies is individually assessed and ranked against each other and compared to industry averages.Using the most ...

November 2012 205 pages

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

US$ 195.00

... examines the Causes of ADHD including Genetics Environmental and Social causes. Attention Deficit Hyperactivity Disorder ADHD is one of the more common mental ... settings including home school and in relationships with peers. If untreated the disorder can have long-term adverse effects into adolescence and ...

October 2012 95 pages

Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules

US$ 7,495.00

Charting the Future Multiple Sclerosis Market LandscapeOver the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary d...

August 2012

ERS 2012 Preview: QVA-149-LABA/LAMA FDC well Positioned to Take a Share in the Second Line and Third Line Setting for Treatment of COPD

US$ 90.00

... of QVA-149 from fifth and final successful pivotal clinical study result (SPARK) from IGNITE program on August 30th, 2012. The fixed dose LABA ... in the US and 2012-2013 in the EU and hence any market share loss would be immaterial from Pfizer perspective. The LABA/LAMA FDC will also ...

August 2012 3 pages

Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module

US$ 4,995.00

Analyse the latest global RA market players and products, and start mapping your future market parameters with Therapy Trends’ Consensus Outlook: Rheumatoid Arthritis, which includes the following com...

July 2012 245 pages

Therapy Trends: Rheumatoid Arthritis -- KOL Insight and Consensus Outlook Modules

US$ 7,495.00

What the future holds Over the next few years, the global Rheumatoid Arthritis (RA) market is expected to grow from $16.5 billion in 2011 to $23.4 billion in 2016. This expansion of the market will b...

July 2012 245 pages

Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module

US$ 4,995.00

Therapy Trends KOL Insight: Rheumatoid Arthritis analyses the current and predicted key issues, clinical advances and late-stage pipeline products in the international and US RA markets. KOL Insight g...

July 2012 245 pages

GILEAD - After HIV -Poised to Deliver the Best Anti-Viral Treatment Options for HCV!

US$ 90.00

Gilead’s supremacy in the HIV space in 2012-18 should remain intact with the successful launch of ... , please read our report released on 3rd May, 2012 on Gilead titled “After HIV -Poised to Deliver the Best Anti-Viral Treatment Options for HCV!”

May 2012 9 pages

India IVF Treatment Market Analysis

US$ 500.00

... , pelvic inflammatory diseases, etc. Today, arrays of treatment options to treat infertility are readily available in India. These include medications for ovulation induction ... IUI, IVF, and ICSI (intra cytoplasmic sperm injection). India has become one of the favored destinations for infertility treatments such as IVF due to several ...

May 2012 40 pages

Osteoporosis Therapeutics: Market Research Report

US$ 4,500.00

This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following Therapeutic Classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, ... 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche ...

April 2012 455 pages

Herpes Simplex Virus Treatment: Market Research Report

US$ 4,600.00

This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, ... , Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, and Vical. Market data and analytics are derived from primary and secondary ...

March 2012 300 pages

Global Protein Therapeutics Market Forecast to 2015

US$ 1,800.00

Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most effective clinical methods to treat w...

March 2012 160 pages

Therapy Trends: Multiple Sclerosis

US$ 4,995.00

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse futu...

March 2012 160 pages

JAPAN DOMESTIC PHARMA- Competitive Landscape of Leading Therapy Classes - UPDATE

US$ 600.00

In this updated issue of ‘Japan-Domestic Pharma Market Summary’ for 2012, we present major 10 Thx Class in Japan which covers ~40% of total Japan domestic pharma market (~¥8.0 trillion). This will ... breakthroughs in each class – which includes products from all pharma companies operating in Japan including MNCs.

March 2012 27 pages

VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!

US$ 140.00

... with G551D mutation), we see little risk to Vertex (VRTX) profitability for at least next three years ... of IL28B CC Genotype. Vertex has also accelerated the pace of developing IFN-free drugs to remain in the ... 14th Feb., 2012 on Vertex titled “IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet ...

February 2012 12 pages

GILEAD - Providing the Best Antiviral Treatment Options for HIV and HCV!

US$ 140.00

Gilead (GILD) is poised for further growth, based on the FY12 ... GILD a step closer towards its goal to deliver the “best-in-class IFN-free oral pill” for HCV. Other acquisitions ... read our report released on 10th Feb., 2012 on Gilead Sciences titled “Providing the Best Antiviral Treatment Options for HIV and HCV!”

February 2012 11 pages

Gene Therapy: Market Research Report

US$ 4,500.00

This report analyzes the Global market for Gene Therapy in US$ Million. Annual estimates and forecasts are provided for the period 2009 through ... GenVec, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Transgene, and Vical Inc. Market data and analytics are derived from primary and secondary research. ...

January 2012 459 pages

Oxygen Therapy: Market Research Report

US$ 1,995.00

... anecdotes, market briefs, and concise summaries of research findings. The report offers an aerial view of the global oxygen therapy industry, identifies major short to medium term market challenges, and growth drivers. Regional markets elaborated upon include United States ...

December 2011 70 pages

Global HIV Therapeutics Market Analysis

US$ 1,200.00

HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete ef...

December 2011 70 pages

Competitor Analysis: HIV Small Molecule Therapeutics

US$ 642.00

The present Competitive Intelligence report about HIV Small Molecule Therapeutics used to treat human immunodeficiency virus (HIV) infections provides a competitor evaluation in the field of marketed...

December 2011 100 pages

World Market for Prescription Arthritis Treatments

US$ 3,500.00

... management. This Kalorama Information report, The World Market for Prescription Arthritis Treatments, details the market for these treatments. The report provides ... There are several issues and trends that are shaping this market. Some of the topics, discussed in this report include: US Economic Impact ...

November 2011 150 pages

Autoimmune Disease Therapeutics: Market Research Report

US$ 4,500.00

This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple ... 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 112 companies including many key and niche ...

October 2011 749 pages

Multiple Myeloma Therapeutics: Market Research Report

US$ 4,500.00

This report analyzes the worldwide markets for Multiple Myeloma Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, ... , Inc., Millennium Pharmaceuticals, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary ...

October 2011 595 pages

Overactive Bladder (OAB) Therapeutics: Market Research Report

US$ 4,500.00

This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million. The report provides separate comprehensive analytics for ... ., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...

August 2011 279 pages

Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report

US$ 4,500.00

This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year ...

August 2011 433 pages

Global Protein Therapeutics Market Analysis

US$ 1,800.00

Single User PDF Format: US$ 1,800.00 Multi-User License: US$ 2,800.00 Hard Copy: US$ 2,200.00 CD-ROM: US$ 2,200.00 Within the global pharmaceutical industry, protein therapeutics has b...

July 2011 180 pages

MEDIVIR AB, Outperform, Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment.

US$ 90.00

Medivir’s Xerese fetched $45m for the company from Meda AB for US, ... , please read our report released on 29th June on MVIR titled “Monetizing Cold Sores to Focus On Improved Protease Inhibitors for HCV Treatment” and ...

June 2011 2 pages

US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma

US$ 500.00

... decisions Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists. ... with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow ...

April 2011 28 pages

US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma

US$ 500.00

... that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal ... Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists ...

April 2011 35 pages

US Oncologist Survey: Optimizing Treatment for Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

US$ 500.00

... that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal ... Barriers to optimal patient care Confidence in treatment Data has been synthesized to show all responses and direct quotes from the oncologists ...

April 2011 26 pages

US Oncologist Survey: Optimizing Treatment for Advanced Non-Hodgkin's Lymphoma

US$ 1,200.00

... . This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of specific patient types. Patient situations: Asymptomatic indolent lymphoma Elderly infirm patient with advanced follicular lymphoma Relapsed ...

April 2011 61 pages

Competitor Analysis RNA Therapeutics in Clinical Development

US$ 561.00

... online work with the project data to print or export an individual report. Although there are only two approved and marketed RNA based ... CpG Oligonucleotides Corporate Clinical Stage RNA Therapeutics R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but ...

March 2011

Competitor Analysis: Targeted Therapy of Obesity

US$ 706.00

... aminopeptidase 2 (MetAP2) Inhibitors f) Other Metabolic Modifiers 6) Various Approaches 7) Unspecified Targets Corporate Targeted Therapy of Obesity R&D Pipelines About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D ...

March 2011 80 pages

RNA Therapeutics Pipeline Database: 1-Year Subscription

US$ 847.00

... (RNAi) or Locked Nucleic Acid (LNA) RNA. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of ... illustrate the database. Purchase of the subscription provides a 1-year online access to the data of the RNA Therapeutics Pipeline Database. Credentials to access ...

March 2011

Filters

Search

Publishers

23
1
97
2
21
16
2
2
2
3
8
1
1
1
6
126
1
1
2
10
8
1
22
8
2
2
1
70
3
2
21
2
4
1
2
2
6
10
8
1
9
2
1
3
1
1
4
22
6
2
3
1
15
18
6
1
2
18
17
1
2
5
1
19
32
19
27
19
5
324
17
16
2
4
1
17

Regions

1
1
1
2
1
2
1
1
1
5
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
2
10
1
17
14
2
1
2
1
13
3
3
1
2
1
1
1
2
2
2
1
2
21
1
1
2
12
10
4
31
942
1

Price

Date

Pages

Offers

97
21
5
1